Therapy Detail

Therapy Name GVAX colorectal cancer vaccine
Therapy Description

GVAX colorectal cancer vaccine is composed of irradiated colorectal cancer (CRC) cells engineered to express GM-CSF, which induces T-cell response against CRC cells (PMID: 24832153).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
GVAX colorectal cancer vaccine GVAX colorectal cancer vaccine is composed of irradiated colorectal cancer (CRC) cells engineered to express GM-CSF, which induces T-cell response against CRC cells (PMID: 24832153).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01966289 Phase I Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) Active, not recruiting